Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 8,312,100,000	$ 6,488,000,000	$ 15,272,100,000	$ 14,298,000,000
U.S.
Disaggregation of Revenue [Line Items]
Revenue	5,531,400,000	3,934,800,000	9,967,600,000	9,109,400,000
Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,780,700,000	2,553,300,000	5,304,600,000	5,188,700,000
Diabetes
Disaggregation of Revenue [Line Items]
Revenue	5,010,900,000	3,438,200,000	9,201,300,000	6,826,300,000
Diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenue	3,781,400,000	2,292,200,000	6,856,400,000	4,568,700,000
Diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,229,500,000	1,146,000,000	2,344,900,000	2,257,600,000
Trulicity®
Disaggregation of Revenue [Line Items]
Revenue	1,812,500,000	1,911,900,000	3,789,600,000	3,653,200,000
Trulicity® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,371,300,000	1,430,100,000	2,918,700,000	2,744,100,000
Trulicity® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	441,200,000	481,700,000	871,000,000.0	909,100,000
Mounjaro®
Disaggregation of Revenue [Line Items]
Revenue	979,700,000	16,000,000.0	1,548,200,000	16,000,000.0
Mounjaro® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	915,700,000	12,600,000	1,452,200,000	12,600,000
Mounjaro® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	64,000,000.0	3,400,000	96,000,000.0	3,400,000
Jardiance
Disaggregation of Revenue [Line Items]
Revenue	668,300,000	461,000,000.0	1,245,800,000	880,400,000
Jardiance | U.S.
Disaggregation of Revenue [Line Items]
Revenue	386,100,000	250,700,000	715,600,000	480,400,000
Jardiance | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	282,200,000	210,300,000	530,200,000	400,000,000.0
Baqsimi
Disaggregation of Revenue [Line Items]
Revenue	613,900,000	29,000,000.0	645,400,000	58,200,000
Baqsimi | U.S.
Disaggregation of Revenue [Line Items]
Revenue	606,200,000	21,800,000	629,300,000	44,300,000
Baqsimi | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	7,700,000	7,200,000	16,100,000	13,900,000
Humalog®
Disaggregation of Revenue [Line Items]
Revenue	440,400,000	447,100,000	901,400,000	1,065,300,000
Humalog® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	229,800,000	238,800,000	501,400,000	607,700,000
Humalog® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	210,600,000	208,300,000	400,000,000.0	457,600,000
Humulin®
Disaggregation of Revenue [Line Items]
Revenue	205,300,000	274,000,000.0	457,300,000	547,200,000
Humulin® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	144,300,000	202,300,000	343,100,000	392,800,000
Humulin® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	61,000,000.0	71,700,000	114,200,000	154,500,000
Basaglar®
Disaggregation of Revenue [Line Items]
Revenue	154,200,000	174,200,000	363,500,000	365,700,000
Basaglar® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	83,000,000.0	95,800,000	218,400,000	215,100,000
Basaglar® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	71,200,000	78,400,000	145,200,000	150,600,000
Other diabetes
Disaggregation of Revenue [Line Items]
Revenue	136,600,000	125,000,000.0	250,100,000	240,300,000
Other diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenue	45,000,000.0	40,100,000	77,700,000	71,700,000
Other diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	91,600,000	85,000,000.0	172,200,000	168,500,000
Oncology
Disaggregation of Revenue [Line Items]
Revenue	1,671,000,000	1,368,700,000	3,027,000,000	2,721,700,000
Oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	935,000,000.0	819,000,000.0	1,688,400,000	1,602,700,000
Oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	736,000,000.0	549,800,000	1,338,600,000	1,119,000,000
Verzenio®
Disaggregation of Revenue [Line Items]
Revenue	926,800,000	588,500,000	1,677,700,000	1,057,900,000
Verzenio® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	588,600,000	384,300,000	1,049,600,000	685,700,000
Verzenio® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	338,200,000	204,200,000	628,000,000.0	372,100,000
Cyramza®
Disaggregation of Revenue [Line Items]
Revenue	260,300,000	231,300,000	497,000,000.0	461,500,000
Cyramza® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	115,000,000.0	92,600,000	215,600,000	171,800,000
Cyramza® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	145,300,000	138,600,000	281,400,000	289,700,000
Erbitux®
Disaggregation of Revenue [Line Items]
Revenue	162,500,000	140,800,000	292,400,000	263,400,000
Erbitux® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	145,500,000	125,100,000	264,200,000	234,700,000
Erbitux® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	17,000,000.0	15,700,000	28,100,000	28,700,000
Alimta®
Disaggregation of Revenue [Line Items]
Revenue	60,900,000	227,700,000	119,100,000	571,700,000
Alimta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	17,900,000	171,700,000	38,000,000.0	425,900,000
Alimta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	43,100,000	56,100,000	81,200,000	145,800,000
Other oncology
Disaggregation of Revenue [Line Items]
Revenue	260,500,000	180,400,000	440,800,000	367,200,000
Other oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	68,000,000.0	45,300,000	121,000,000.0	84,600,000
Other oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	192,400,000	135,200,000	319,900,000	282,700,000
Immunology
Disaggregation of Revenue [Line Items]
Revenue	928,500,000	796,500,000	1,706,300,000	1,544,600,000
Immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	523,100,000	422,000,000.0	877,600,000	800,500,000
Immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	405,400,000	374,500,000	828,600,000	744,100,000
Taltz®
Disaggregation of Revenue [Line Items]
Revenue	703,900,000	606,200,000	1,230,800,000	1,094,300,000
Taltz® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	472,300,000	411,600,000	784,500,000	718,800,000
Taltz® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	231,600,000	194,700,000	446,300,000	375,500,000
Olumiant®
Disaggregation of Revenue [Line Items]
Revenue	218,900,000	186,200,000	447,800,000	441,800,000
Olumiant® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	50,800,000	10,400,000	93,100,000	81,700,000
Olumiant® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	168,100,000	175,800,000	354,600,000	360,100,000
Other immunology
Disaggregation of Revenue [Line Items]
Revenue	5,700,000	4,000,000.0	27,700,000	8,500,000
Other immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Other immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	5,700,000	4,000,000.0	27,700,000	8,500,000
Neuroscience
Disaggregation of Revenue [Line Items]
Revenue	387,200,000	389,900,000	747,700,000	787,700,000
Neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	160,900,000	144,800,000	305,400,000	298,100,000
Neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	226,300,000	245,200,000	442,300,000	489,500,000
Emgality®
Disaggregation of Revenue [Line Items]
Revenue	169,300,000	157,500,000	323,600,000	306,700,000
Emgality® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	118,800,000	108,600,000	227,500,000	216,900,000
Emgality® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	50,500,000	48,900,000	96,100,000	89,800,000
Other neuroscience
Disaggregation of Revenue [Line Items]
Revenue	217,900,000	232,400,000	424,100,000	481,000,000.0
Other neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	42,100,000	36,200,000	77,900,000	81,200,000
Other neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	175,800,000	196,300,000	346,200,000	399,700,000
Other
Disaggregation of Revenue [Line Items]
Revenue	314,600,000	494,700,000	589,900,000	2,417,700,000
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	131,000,000.0	256,900,000	239,800,000	1,839,200,000
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	183,500,000	237,900,000	350,100,000	578,500,000
Forteo®
Disaggregation of Revenue [Line Items]
Revenue	148,000,000.0	138,500,000	270,300,000	275,900,000
Forteo® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	97,400,000	78,500,000	168,000,000.0	148,700,000
Forteo® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	50,600,000	60,000,000.0	102,300,000	127,200,000
Cialis®
Disaggregation of Revenue [Line Items]
Revenue	115,600,000	147,000,000.0	215,900,000	364,700,000
Cialis® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	9,200,000	10,800,000	16,800,000	17,700,000
Cialis® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	106,400,000	136,200,000	199,100,000	347,000,000.0
COVID-19 antibodies
Disaggregation of Revenue [Line Items]
Revenue	0	129,100,000	0	1,598,900,000
COVID-19 antibodies | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0	129,100,000	0	1,584,300,000
COVID-19 antibodies | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	14,700,000
Other
Disaggregation of Revenue [Line Items]
Revenue	51,000,000.0	80,100,000	103,700,000	178,200,000
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	24,400,000	38,500,000	55,000,000.0	88,500,000
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	$ 26,500,000	$ 41,700,000	$ 48,700,000	$ 89,600,000